mRNA Beyond COVID: Scaling Platform Technologies for Oncology

The mRNA platform's success in vaccines is driving rapid expansion into oncology and immunotherapy, but manufacturing readiness for these complex applications has become the rate-limiting factor in commercialization.

Key Discussion Points:

- Platform scalability diverges sharply between high-volume vaccine production and low-volume, personalized oncology therapeutics—requiring fundamentally different manufacturing infrastructure

- Personalized and combination mRNA approaches exponentially increase manufacturing complexity—creating CDMO capacity bottlenecks and cost structures that challenge commercial viability

- Regulatory frameworks for mRNA oncology therapeutics remain in flux—creating strategic risk for companies investing in manufacturing infrastructure before pathway clarity